HALO · XBRL financial data

Halozyme Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (HALO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	268	443	660	829	1,015	1,397
Cost of goods and services sold	43	81	139	192	159	229
Research and development	34	36	67	76	79	—
Selling, general and administrative	46	50	144	149	154	207
Operating income (loss)	144	276	268	338	551	469
Interest expense	20	8	17	19	18	18
Other income (expense)	5	1	1	16	24	21
Income tax expense (benefit)	0	(154)	47	67	113	150
Net income (loss)	129	403	202	282	444	317
Earnings per share, basic USD per share	0.95	2.86	1.48	2.13	3.50	2.64
Earnings per share, diluted USD per share	0.91	2.74	1.44	2.10	3.43	2.56
Weighted average shares, basic millions of shares	136	141	137	132	127	120
Weighted average shares, diluted millions of shares	141	147	141	134	129	124

Fiscal years (HALO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	148	119	234	118	116	134
Marketable securities	220	622	129	—	—	—
Accounts receivable	98	91	231	233	288	426
Inventory	61	54	100	128	142	176
Prepaid and other current assets	28	40	45	49	39	65
Total current assets	555	926	739	746	1,085	825
Property and equipment, net	11	7	35	38	41	44
Right-of-use asset	3	2	40	37	34	38
Goodwill	—	0	409	417	417	580
Total assets	580	1,104	1,842	1,733	2,063	2,525
Accounts payable	2	2	18	12	10	21
Accrued liabilities	20	24	97	101	129	156
Current portion of long-term debt	397	89	13	0	0	0
Total current liabilities	421	117	131	112	139	177
Long-term debt	0	787	1,493	1,499	1,506	2,143
Total liabilities	—	—	1,672	1,649	1,700	2,477
Retained earnings (accumulated deficit)	(475)	(59)	143	91	360	55
Total stockholders' equity	151	197	170	84	364	49
Total liabilities and equity	580	1,104	1,842	1,733	2,063	2,525
Common shares outstanding (cover page) millions of shares	135	138	135	127	123	118

Fiscal years (HALO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	129	403	202	282	444	317
Stock-based compensation	17	21	24	37	43	52
Depreciation and amortization	3	3	6	11	10	11
Net cash from operating activities	55	299	240	389	479	652
Purchases of property and equipment	3	1	5	15	11	7
Net cash from investing activities	78	(406)	(487)	(97)	(263)	(546)
Share repurchases	150	350	200	402	250	342
Net cash from financing activities	(106)	78	362	(408)	(219)	(85)
Net change in cash	28	(29)	115	(116)	(3)	21

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.